Lake Street Maintains Buy on Castle Biosciences, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Thomas Flaten maintains a Buy rating on Castle Biosciences (NASDAQ:CSTL) but lowers the price target from $41 to $32.
June 05, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Castle Biosciences' Buy rating is maintained by Lake Street analyst Thomas Flaten, but the price target is lowered from $41 to $32.
The news directly mentions Castle Biosciences (CSTL) and the lowered price target by Lake Street analyst Thomas Flaten. While the Buy rating is maintained, the lower price target may cause some uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100